• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Proc Natl Acad Sci USA. Optimizing infectious disease interventions during an emerging epidemic.

Giuseppe

Emeritus
Optimizing infectious disease interventions during an emerging epidemic. (Proc Natl Acad Sci USA, abstract, edited)

19. Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):923-8. Epub 2009 Dec 28.

Optimizing infectious disease interventions during an emerging epidemic.

Wallinga J, van Boven M, Lipsitch M. - Centre for Infectious Disease Control, National Institute for Public Health and the Environment, 3720 BA Bilthoven, Netherlands. jacco.wallinga@rivm.nl

The emergence and global impact of the novel influenza A(H1N1)v highlights the continuous threat to public health posed by a steady stream of new and unexpected infectious disease outbreaks in animals and humans. Once an emerging epidemic is detected, public health authorities will attempt to mitigate the epidemic by, among other measures, reducing further spread as much as possible. Scarce and/or costly control measures such as vaccines, anti-infective drugs, and social distancing must be allocated while epidemiological characteristics of the disease remain uncertain. Here we present first principles for allocating scarce resources with limited data. We show that under a broad class of assumptions, the simple rule of targeting intervention measures at the group with the highest risk of infection per individual will achieve the largest reduction in the transmission potential of a novel infection. For vaccination of susceptible persons, the appropriate risk measure is force of infection; for social distancing, the appropriate risk measure is incidence of infection. Unlike existing methods that rely on detailed knowledge of group-specific transmission rates, the method described here can be implemented using only data that are readily available during an epidemic, and allows ready adaptation as the epidemic progresses. The need to observe risk of infection helps to focus the ongoing planning and design of new infectious disease surveillance programs; from the presented first principles for allocating scarce resources, we can adjust the prioritization of groups for intervention when new observations on an emerging epidemic become available.

PMID: 20080777 [PubMed - indexed for MEDLINE]

PMCID: PMC2818907 [Available on 2010/7/12]

Publication Types:

* Research Support, N.I.H., Extramural

MeSH Terms:

* Antiviral Agents/therapeutic use
* Communicable Disease Control/methods*
* Disease Outbreaks/prevention & control*
* Humans
* Incidence
* Influenza A Virus, H1N1 Subtype/pathogenicity*
* Influenza Vaccines
* Influenza, Human/epidemiology*
* Influenza, Human/immunology
* Influenza, Human/prevention & control
* Influenza, Human/transmission
* Resource Allocation/methods
* Resource Allocation/organization & administration
* Risk Factors
* Vaccination/statistics & numerical data
* Viral Vaccines/therapeutic use*
* World Health

Substances:

* Antiviral Agents
* Influenza Vaccines
* Viral Vaccines

Grant Support:

* 1U54GM088558/GM/NIGMS NIH HHS/United States
* 5U01GM076497/GM/NIGMS NIH HHS/United States

-
------
 
Back
Top